Abstract Background: Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia. Previous studies showed that rhythm and rate control strategies are associated with similar rates of mortality and serious morbidity. Beta blockers (BB) and calcium channel blockers (CCB) are commonly used and the selection between these two medications depends on personal preference. Objectives: To compare real-time capability of BB and CCB for the treatment of rapid AF and to estimate their efficacy in redu...
Dec 03, 2022•2 min•Season 1Ep. 82
Abstract The harm of heart failure mainly causes patients to develop dyspnea, fatigue, fluid retention, and other symptoms, which impair patients' activity tolerance and lead to a dramatic decrease in patients' quality of life. The purpose of this study was to verify whether metoprolol regulates AKAP5 expression and test the role of AKAP5 postinjury in mitigating cardiac infarction-associated tissue remodeling and fibrosis. Sprague-Dawley (SD) rats underwent coronary artery ligation (CAL), which...
Dec 03, 2022•2 min•Season 1Ep. 81
Abstract Background: Ticagrelor is one of the most recent antiplatelet drugs to be approved to treat ischemic heart disease. Its efficacy may exceed aspirin in improving clinical outcomes in patients with acute ischemic stroke who are ineligible for rt-PA. Objectives: We evaluated the safety regarding hemorrhagic complications (as a primary endpoint) and the efficacy (as a secondary endpoint) of a 180-mg loading dose of ticagrelor given within 9 h from the onset of the first-ever non-cardioembol...
Dec 03, 2022•2 min•Season 1Ep. 80
Efficacy and Safety of Sustained-Release Metoprolol with Dronedarone After Radiofrequency Ablation of Paroxysmal Atrial Fibrillation: A Propensity Matched Analysis Am J Cardiol. 2022 Oct 15;S0002-9149(22)00898-0 Abstract The high early recurrence (ER) rate after radiofrequency catheter ablation (RFCA) seriously affects the prognosis of patients with atrial fibrillation (AF), and there are still controversies regarding the best preventive drugs for postoperative recurrence. A single-center retros...
Nov 02, 2022•3 min•Season 1Ep. 79
Incidence and predictors of heart failure after acute coronary Syndrome: The CORALYS registry Int J Cardiol. 2022 Oct 25;S0167-5273(22)01658-8 Abstract Background: Previous studies investigating predictors of Heart Failure (HF) after acute coronary syndrome (ACS) were mostly conducted during fibrinolytic era or restricted to baseline characteristics and diagnoses prior to admission. We assessed the incidence and predictors of HF hospitalizations among patients treated with percutaneous coronary ...
Nov 02, 2022•3 min•Season 1Ep. 78
Effect of β-Blocker Therapy on the Level of Soluble ST2 Protein in Pediatric Dilated Cardiomyopathy Medicina (Kaunas). 2022 Sep 23;58(10):1339 Abstract Background and Objectives: A prognosis for kids with pediatric dilated cardiomyopathy (PDCM) is urgently needed to identify high-risk patients. This study aimed to determine the association of levels and soluble suppression of tumorigenicity 2 (sST2) and medical therapy of β-blocker inhibitors with the risk of adverse events in PDCM. Materials an...
Nov 02, 2022•2 min•Season 1Ep. 77
Clopidogrel resistance and ticagrelor replacement in dual antiplatelet therapy for carotid artery stenting Ann Vasc Surg. 2022 Oct 18;S0890-5096(22)00640-9 Abstract Objective: Resistance to the pharmacological effect of clopidogrel in patients undergoing dual antiplatelet therapy for carotid stenting may increase the risk of periprocedural neurological events. The purpose of the study was to describe the phenomenon of clopidogrel resistance in a series of patients undergoing carotid stenting. Me...
Nov 02, 2022•2 min•Season 1Ep. 76
Abstract Aim: This meta-analysis aims to look at the impact of early intravenous Metoprolol in ST-segment elevation myocardial infarction (STEMI) before percutaneous coronary intervention (PCI) on infarct size, as measured by cardio magnetic resonance (CMR) and left ventricular ejection fraction. Methods: We searched the following databases: PubMed, Scopus, Cochrane library, and Web of Science. We included only randomized control trials that reported the use of early intravenous Metoprolol in ST...
Oct 04, 2022•2 min•Season 1Ep. 75
Abstract Background: Thromboembolic complications are one of the major periprocedural complications following neuroendovascular procedures. Dual antiplatelet therapy (DAPT) with aspirin and clopidogrel remain the principal agents for prevention of thromboembolic complications. However, clopidogrel resistance is associated with higher risk of thromboembolic complications. This study investigated the safety and efficacy of DAPT with ticagrelor and aspirin in patients undergoing intracranial stenti...
Oct 04, 2022•3 min•Season 1Ep. 74
The study is a double-blind, placebo-controlled, randomized TWILIGHT trial (Ticagrelor with Aspirin or Alone in High-Risk Patients After Coronary Intervention) that compared the use of ticagrelor with or without aspirin in the patients undergoing PCI. The study enrolled patients undergoing high-risk percutaneous coronary intervention. After 3 months of treatment with ticagrelor plus aspirin, event-free and adherent patients remained on ticagrelor and were randomly assigned to receive aspirin or ...
Oct 04, 2022•2 min•Season 1Ep. 72
Ticagrelor provides more rapid, potent, and consistent anti-platelet efficacy than clopidogrel. This study is a randomized trial that aimed to evaluate the anti-inflammatory effects of ticagrelor on thrombus aspirated from the ST-elevation myocardial infarction (STEMI) patients. The results were compared against clopidogrel. The study was conducted among 98 patients with STEMI and intended percutaneous coronary intervention (PCI). The patients were divided into two groups to receive clopidogrel ...
Oct 04, 2022•2 min•Season 1Ep. 72
Beta-blockers in acute coronary syndrome: does rhythm matter? The study aimed to assess and compare the in-hospital and 1-year prognostic impact of BB prescription after acute coronary syndrome (ACS), in patients with previous or de novo AF, and in patients with sinus rhythm (SR). It has been already known that beta-blockers (BB) are recommended in patients with previous acute myocardial infarction (AMI), aiming to reduce morbidity and mortality. Their benefit is greater in patients with associa...
Sep 02, 2022•2 min•Season 1Ep. 71
Metoprolol improves left ventricular longitudinal function at rest and during exercise in obstructive hypertrophic cardiomyopathy The following study aimed to characterize left ventricular (LV) systolic function by segmental and global longitudinal strain echocardiography and to investigate changes in relation to exercise, and the effect of standard treatment with beta-blockers. What we already know is that hypertrophic cardiomyopathy (HCM) patients with outflow obstruction often experience symp...
Sep 02, 2022•2 min•Season 1Ep. 70
Bleeding outcomes with ticagrelor versus clopidogrel in patients with the acute coronary syndrome; a focused analysis from the multicenter CREA ARIAM Andalucia registry The question that usually arises is that, “What is the incidence, types, timing, and prognostic relevance of major bleeding events in ACS patients treated with ticagrelor or clopidogrel in contemporary practice”? What we already know is that with the use of various antithrombotic agents in acute coronary syndrome (ACS), bleeding ...
Sep 02, 2022•2 min•Season 1Ep. 69
Conservative management in a contemporary cohort of patients with acute coronary syndrome: Results from the FORCE-ACS registry The study aimed to evaluate conservative management compared with revascularization therapy in ACS patients, focused on ischemic and bleeding outcomes and to provide insights into the physician’s rationale of choice for conservative management. Currently, the evidence for conservatively managed patients with the acute coronary syndrome (ACS) is scarce. A total of 5379 AC...
Sep 02, 2022•2 min•Season 1Ep. 68
Abstract The occurrence of coronary artery embolism (CE) has been associated with various clinical conditions, including aortic and mitral prosthetic heart valve implantation, atrial fibrillation (AF), dilated cardiomyopathy, neoplasia, infective endocarditis, atrial septal defect, cardiac tumors, and hypercoagulable states. CE is also a rare cause of myocardial infarction (MI), with a prevalence of about 5%, a figure probably underestimated. The purpose of this article was to determine the curr...
Aug 05, 2022•2 min•Season 1Ep. 67
Abstract Introduction: Patients undergoing acute percutaneous coronary intervention receive dual antiplatelet therapy for secondary prevention. Recurrent myocardial infarction or bleedings are possibly due to under- or overdosing of antiplatelet therapy in relation to body size. Methods: We correlated residual platelet aggregation with body mass index, body surface area, lean body mass and blood volume in 220 patients on prasugrel (n = 121) or ticagrelor (n = 99). Results: Platelet aggregation o...
Aug 05, 2022•1 min•Season 1Ep. 66
Abstract Objective: Beta-blockers are first-line anti-impulse therapy in patients presenting with acute type B aortic dissection (TBAD). However, little is understood about their impact after aortic repair. The aim of this study was to evaluate the role of postoperative beta-blocker use on outcomes of thoracic endovascular aortic repair (TEVAR) in TBAD. Methods: The Vascular Quality Initiative database was queried for all patients undergoing TEVAR for TBAD from 2012 to 2020. Aortic-related reint...
Aug 05, 2022•4 min•Season 1Ep. 65
Abstract Background: This meta-analysis mainly aimed to compare the impact of prasugrel and ticagrelor on platelet reactivity (PR) in patients with acute coronary syndrome (ACS). Methods: We searched four electronic databases to identify randomized controlled trials and cohort studies comparing the impact of prasugrel and ticagrelor on PR in patients with ACS. We performed group analyses according to three detection methods, drug dose [loading dose (LD) and maintenance dose (MTD)] and LD effect ...
Aug 05, 2022•2 min•Season 1Ep. 64
· ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation acute (NSTE-ACS) coronary syndrome are referred to collectively as acute coronary syndrome (ACS) · The latter includes non-ST-segment elevation myocardial infarction and unstable angina pectoris (NSTEMI). Cardiovascular catheterization must be immediately recommended in cases of STEMI. · The management and diagnosis of NSTE-ACS are more difficult. The most recent ESC treatment guidelines for NSTE-ACS were released ...
Jul 01, 2022•1 min•Season 1Ep. 62
The authors aimed to determine the efficacy of comprehensive pharmaceutical care intervention that included face-to-face education about the disease, healthy lifestyle, medication adherence, drug related problems management and goal setting which was added to cardiac rehabilitation program in improving echocardiographic parameters, nutritional status and High sensitivity C-Reactive Protein in patients with acute coronary syndrome. In this study, out of a total of 40 patients, 20 patients were ra...
Jul 01, 2022•2 min•Season 1Ep. 61
The authors aimed to evaluate the effects of metoprolol succinate in combination with Entresto (Sacubitril Valsartan Sodium Tablets) on cardiac function and coagulation function in patients with congestive heart failure (CHF). A total of 120 patients were included in this study and patients were randomly assigned to control group and study group. In the control group, patients were prescribed with metoprolol succinate sustained-release tablets and the patients in the study group were prescribed ...
Jul 01, 2022•2 min•Season 1Ep. 60
Observational studies that failed to take time-dependent confounders into account have lately called into doubt the net therapeutic advantage of ticagrelor over clopidogrel in acute coronary syndrome (ACS). The authors aimed to evaluate the comparative safety and efficacy of ticagrelor vs. clopidogrel in real-life setting by taking into account the non-adherence of the therapy. The following are key points to remember from this prospective, multi-cohort study on the outcomes in ACS patients disc...
Jul 01, 2022•2 min•Season 1Ep. 59
Transcatheter aortic valve replacement (TAVR) has become a well-established therapy for patients with severe, symptomatic aortic stenosis who are at intermediate-to-high surgical risk over last decade. Aortic stenosis and coronary artery disease (CAD) have similar risk factors and pathogenic pathways, and 40% to 75% of TAVR patients had significant CAD. In patients with severe CAD following aortic valve replacement, current recommendations advocate coronary revascularization (Class IIa, Level of...
May 31, 2022•2 min•Season 1Ep. 58
Ticagrelor lowers ischemia risk in patients who have had a previous heart attack (MI). It's uncertain whether the risks of ischemic stroke and the advantages of long-term P2Y12 inhibition in this cohort are stable over time. The goal of the trial was to see how ischemia risk changed over time and if the efficacy and safety of ticagrelor were the same early and late after randomization. The PEGASUS-TIMI (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Comp...
May 31, 2022•2 min•Season 1Ep. 57
Patients at a high risk of bleeding (HBR) are a common subgroup of those receiving percutaneous coronary intervention (PCI). After a short period of dual antiplatelet treatment (DAPT), early aspirin discontinuation has emerged as a bleeding prevention technique. It has been demonstrated by TWILIGHT trial that ticagrelor monotherapy is an effective and safe bleeding prevention approach for high-risk PCI patients, following a short course of DAPT. TWILIGHT-HBR was conducted with the pre-specified ...
May 31, 2022•2 min•Season 1Ep. 56
After a minimum term of dual antiplatelet medication, monotherapy with a P2Y12 inhibitor is an emerging strategy for reducing the risk of bleeding after percutaneous coronary intervention (PCI). This Ticagrelor with Aspirin or Alone in High-Risk Patients after Coronary Intervention (TWILIGHT) trial was designed to test the hypothesis that a 3-month course of dual antiplatelet therapy with ticagrelor plus aspirin followed by ticagrelor monotherapy is superior to ticagrelor plus aspirin in patient...
May 27, 2022•2 min•Season 1Ep. 55
The optimal timing of oral P2Y12 inhibitors administration is not well-defined even though they remain the main-stay treatment in the management of patients with non–ST-segment elevation acute coronary syndrome. In the theoretical knowledge, administration of an oral P2Y12 inhibitor before defining coronary anatomy provides more ischemic protection while patients are waiting to undergo coronary angiography and reduces the risk of periprocedural thrombotic complications among those undergoing per...
May 27, 2022•2 min•Season 1Ep. 54
In the TICO randomized clinical trial, stopping aspirin was tested as a bleeding reduction method after short-term dual anti-platelet treatment (DAPT). However, ticagrelor monotherapy has not been studied in patients with acute coronary syndromes solely (ACS). The objective of this study was to determine whether moving to ticagrelor monotherapy in patients with ACS treated with drug-eluting stents, after 3 months of DAPT lowers net adverse clinical events compared to ticagrelor-based 12-month DA...
May 27, 2022•3 min•Season 1Ep. 53
This secondary analysis of an open-label randomized controlled clinical trial evaluated whether low-dose triple combination antihypertensive therapy helps patients with mild to moderate hypertension to stay at target blood pressure longer than usual care. The triple therapy combination pill contained telmisartan 20 mg, amlodipine 2.5 mg, and chlorthalidone 12.5 mg. In this triple FDC therapy versus usual care, the main endpoints were between-group differences in time at target compared over 24 w...
May 04, 2022•2 min•Season 1Ep. 52
